Medicare for all will not save millions of dollars

Continue reading

Where are the people who are going to save pharma?

  • The pharma industry continues to be the target of politicians and the media.
  • Pharma’s CEO’s primary customer is Wall Street, not patients.
  • Trade magazines are not discussing the key challenges facing our industry, rather they cater to pharma with awards that that wind up being just a bullet point on resumes.
  • Before the industry can change they need to hire more “pirates” and break the pharma ecosystem that recycles people from one company to another.

Continue reading

Biogen moves the goal posts

  • Eisai and Biogen posted promising data for BAN2401 that lifted its stock and had the pharma trade publications talking breakthrough.
  • But there is a lot of controversy swirling around the study.
  • It seems that Biogen may have moved the goal posts to gain more favorable data endpoints.
  • It’s not about patients, it’s about the stock price and getting investors on board.

Continue reading

Freeze on drug price increases won’t effect patients

  • Several pharmaceutical companies have recently said they’ll delay some of their price increases, under pressure from the Trump administration. But hospitals have made no such concessions, even though they make up a much larger share of total health care spending.
  • Pfizer, Novartis, Merck and other drug makers have said they will delay, freeze or roll back price increases on some of their medicines. Experts largely dismissed those pledges as political bandages with little real effect on patients’ pocketbooks.
  • Drug pricing is the political controversy of the moment, but hospitals cost the health care system far more.  Retail drug spending represents 10% of U.S. health care spending, while hospital and doctor services consume about half of spending.

Continue reading

Will pharma get digital?

  • Only 3% of healthcare advertising is spent on digital.
  • Pharma websites are not designed to engage users they are there to strictly inform people about the advertised drug.
  • An estimated $7.4 billion (£5.5 billion) was wasted on display ads alone in 2016, a figure that will rise to $10.9 billion (£8 billion) by 2021, according to Forrester.
  • Before serving an ad, marketers must gain insight on target audiences. Many take a “spray and pray” approach, hoping to drive performance success.
  • According to AdWeek, only 14% of marketers whitelist sites, with 52% estimating that 10-50% of their marketing spend is lost to fraud.
  • More than half of paid programming impressions are probably fraudulent , while under even the best-case scenario, one-third of those impressions aren’t viewed by an actual person.

Continue reading